Formulations
Oral, sublingual, ODT, and troche microdosing
Why non-injectable GLP-1 products are a separate class with their own — often missing — evidence.
Oral, sublingual, buccal, ODT, and troche GLP-1 products are not equivalent to injections. One approved oral semaglutide exists (Rybelsus); there is no approved oral tirzepatide. Compounded oral and sublingual GLP-1 products are separate, not FDA approved, and their absorption is generally unestablished.
What the evidence shows
- An approved oral semaglutide (Rybelsus) exists and is studied as its own product.
- Injectable GLP-1 evidence is robust for the approved injectable products.
What the evidence does not show
- That compounded oral/sublingual GLP-1 is absorbed comparably — generally unestablished.
- That injectable trial results transfer to compounded oral or ODT formulations.
Why the form matters
Peptides like semaglutide and tirzepatide are broken down in the gut, which is why the approved oral product uses a specific absorption-enhancing formulation and strict dosing conditions. A compounded sublingual drop or troche is a different preparation, and there is little to no evidence that it delivers a comparable, consistent dose. Verify the pharmacy and ingredient identity before relying on any compounded oral product — see pharmacy verification.
Frequently asked questions
Is compounded oral semaglutide the same as Rybelsus?
No. Rybelsus is a specific approved tablet; compounded oral or sublingual semaglutide is a different, non-approved product with unestablished absorption.
Is there an oral tirzepatide?
No FDA-approved oral tirzepatide exists in any form.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.